DDrare: Database of Drug Development for Rare Diseases

Searched query = "Hypoplastic left heart syndrome", "HLHS"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = Allo-hMSCs; Ambrisentan; Autologous (self) mononuclear cells derived from umbilical cord blood; Autologous Human Placental Cord Blood Mononuclear Cells; Autologous Umbilical Cord Blood; Autologous cell-based delivery; Bosentan; C-kit+ cells; Curosurf; Erythropoetin; Longeveron Mesenchymal Stem Cells; METHYLPREDNISOLONE SODIUM SUCCINATE; MPC; Maternal Hyperoxygenation; Maternal hyperoxygenation; Methylprednisolone; Metyyliprednisoloninatriumsuksinaatti; Nitrogen; Normal saline; Oxandrolone; Procedure: Stage II Surgical repair; Rexlemestrocel-L; Sham; Sildenafil; Solu-Medrol; Solu-medrol; Tracleer; Vitamin C

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03779711 (ClinicalTrials.gov)	December 12, 2018	4/12/2018	Intramyocardial Injection of Autologous Umbilical Cord Blood Derived Mononuclear Cells During Surgical Repair of Hypoplastic Left Heart Syndrome	Phase IIb Study of Intramyocardial Injection of Autologous Umbilical Cord Blood Derived Mononuclear Cells During Stage II Surgical Repair of Right Ventricular Dependent Variants of Hypoplastic Left Heart Syndrome (AutoCell-S2)	Hypoplastic Left Heart Syndrome	Biological: Autologous (self) mononuclear cells derived from umbilical cord blood;Procedure: Stage II Surgical repair	Timothy J Nelson, MD, PhD	University of Oklahoma;Children's Hospital of Philadelphia;Children's Hospital Los Angeles;Children's Hospital Colorado;Children's Hospitals and Clinics of Minnesota;Ochsner Health System;Children's of Alabama	Recruiting	N/A	12 Months	All	100	Phase 2	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT03779711
(ClinicalTrials.gov)

December 12, 2018

4/12/2018

Intramyocardial Injection of Autologous Umbilical Cord Blood Derived Mononuclear Cells During Surgical Repair of Hypoplastic Left Heart Syndrome

Phase IIb Study of Intramyocardial Injection of Autologous Umbilical Cord Blood Derived Mononuclear Cells During Stage II Surgical Repair of Right Ventricular Dependent Variants of Hypoplastic Left Heart Syndrome (AutoCell-S2)

Hypoplastic Left Heart Syndrome

Biological: Autologous (self) mononuclear cells derived from umbilical cord blood;Procedure: Stage II Surgical repair

Timothy J Nelson, MD, PhD

University of Oklahoma;Children's Hospital of Philadelphia;Children's Hospital Los Angeles;Children's Hospital Colorado;Children's Hospitals and Clinics of Minnesota;Ochsner Health System;Children's of Alabama

Recruiting

N/A

12 Months

All

100

Phase 2

United States